{"id":"5ari","safety":{"commonSideEffects":[{"rate":"3.8%","effect":"Erectile dysfunction"},{"rate":"2.2%","effect":"Decreased libido"},{"rate":"1.4%","effect":"Breast tenderness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"5-alpha-reductase inhibitors block the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT), a hormone involved in the development of benign prostatic hyperplasia (BPH) and androgenetic alopecia.","oneSentence":"5-alpha-reductase inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:19:57.651Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia"},{"name":"Androgenetic alopecia"}]},"trialDetails":[{"nctId":"NCT04288427","phase":"NA","title":"5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2020-09-25","conditions":"Benign Prostatic Hyperplasia, Prostate Hyperplasia, Prostate Disease","enrollment":120},{"nctId":"NCT02876757","phase":"","title":"5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2003-01","conditions":"BPH, Depression, Suicide","enrollment":186394},{"nctId":"NCT01301599","phase":"PHASE4","title":"Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH)","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2011-01","conditions":"Benign Prostatic Hyperplasia","enrollment":308},{"nctId":"NCT01323998","phase":"","title":"Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01332435","phase":"","title":"Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11","conditions":"Prostatic Hyperplasia","enrollment":6896},{"nctId":"NCT01332487","phase":"","title":"Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Prostatic Hyperplasia","enrollment":4068},{"nctId":"NCT01334723","phase":"","title":"Demonstrating the Clinical and Economic Benefit of 5 Alpha Reductase Inhibitor Adherence in Benign Prostatic Hyperplasia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Prostatic Hyperplasia","enrollment":35032},{"nctId":"NCT01376258","phase":"","title":"Benefits of Adherence to 5-alpha Reductase Inhibitor Treatment in Men With Enlarged Prostate: An Assessment of Medicare and Medicaid Patients Using the MarketScan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Prostatic Hyperplasia","enrollment":28903},{"nctId":"NCT01386983","phase":"","title":"Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Prostatic Hyperplasia","enrollment":332},{"nctId":"NCT01390870","phase":"","title":"Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05","conditions":"Prostatic Hyperplasia","enrollment":400},{"nctId":"NCT01435954","phase":"","title":"Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Benign Prostatic Hyperplasia","enrollment":13551},{"nctId":"NCT01381510","phase":"","title":"Establishing the Benefits of Adherence to Enlarged Prostate Treatment: A Validation Study Linking Adherence to Outcomes Using the Market Scan Database","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Prostatic Hyperplasia","enrollment":54459}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":364,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Proscar® (finasteride)","Avodart® (dutasteride)","Avodart® is a registered trademark of GlaxoSmithKline","Proscar® is a registered trademark of Merck"],"phase":"phase_2","status":"active","brandName":"5ARI","genericName":"5ARI","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-alpha-reductase inhibitor Used for Benign prostatic hyperplasia, Androgenetic alopecia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}